These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8392340)

  • 1. Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice.
    Fischer W; Schudt C; Wendel A
    Biochem Pharmacol; 1993 Jun; 45(12):2399-404. PubMed ID: 8392340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation.
    Sekut L; Yarnall D; Stimpson SA; Noel LS; Bateman-Fite R; Clark RL; Brackeen MF; Menius JA; Connolly KM
    Clin Exp Immunol; 1995 Apr; 100(1):126-32. PubMed ID: 7697910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM; Barnes PJ; Meja K; Giembycz MA
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM; Barnes PJ; Giembycz MA
    Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages.
    Schade FU; Schudt C
    Eur J Pharmacol; 1993 Jan; 230(1):9-14. PubMed ID: 8381357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.
    Badger AM; Olivera DL; Esser KM
    Circ Shock; 1994 Dec; 44(4):188-95. PubMed ID: 7628060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor.
    Prabhakar U; Lipshutz D; Bartus JO; Slivjak MJ; Smith EF; Lee JC; Esser KM
    Int J Immunopharmacol; 1994 Oct; 16(10):805-16. PubMed ID: 7843852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
    Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M
    Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
    Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
    Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide.
    Greten TF; Eigler A; Sinha B; Moeller J; Endres S
    Int J Immunopharmacol; 1995 Jul; 17(7):605-10. PubMed ID: 8586489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.
    Underwood DC; Kotzer CJ; Bochnowicz S; Osborn RR; Luttmann MA; Hay DW; Torphy TJ
    J Pharmacol Exp Ther; 1994 Jul; 270(1):250-9. PubMed ID: 8035322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages.
    Kambayashi T; Jacob CO; Zhou D; Mazurek N; Fong M; Strassmann G
    J Immunol; 1995 Nov; 155(10):4909-16. PubMed ID: 7594495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
    Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
    Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis.
    Taguchi I; Oka K; Kitamura K; Sugiura M; Oku A; Matsumoto M
    Inflamm Res; 1999 Jul; 48(7):380-5. PubMed ID: 10450787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol.
    Dent G; Giembycz MA; Evans PM; Rabe KF; Barnes PJ
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1167-74. PubMed ID: 7996422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram.
    Pettipher ER; Labasi JM; Salter ED; Stam EJ; Cheng JB; Griffiths RJ
    Br J Pharmacol; 1996 Apr; 117(7):1530-4. PubMed ID: 8730750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase 4 inhibition but not beta-adrenergic stimulation suppresses tumor necrosis factor-alpha release in peripheral blood mononuclear cells in septic shock.
    Link A; Selejan S; Maack C; Lenz M; Böhm M
    Crit Care; 2008; 12(6):R159. PubMed ID: 19091080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo.
    Beshay E; Croze F; Prud'homme GJ
    Clin Immunol; 2001 Feb; 98(2):272-9. PubMed ID: 11161985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuation by phosphodiesterase inhibitors of lipopolysaccharide-induced thromboxane release and bronchoconstriction in rat lungs.
    Uhlig S; Featherstone RL; Held HD; Nüsing R; Schudt C; Wendel A
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1453-9. PubMed ID: 9400021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids.
    Sinha B; Semmler J; Eisenhut T; Eigler A; Endres S
    Eur J Immunol; 1995 Jan; 25(1):147-53. PubMed ID: 7843225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.